Sarcopenia and long-term survival outcomes after local therapy for colorectal liver metastasis: a meta-analysis

Waalboer, Ruben B.; Meyer, Yannick; Galjart, Boris; Olthof, Pim B.; Vugt, Jeroen L.A. van; Grünhagen, Dirk J.; Verhoef, Cornelis

doi:10.1016/j.hpb.2021.08.947

Cited by 14 publications

(12 citation statements)

References 46 publications

(127 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current systematic review suggests that sarcopenia negatively affects prognostic outcomes of cancer patients in terms of survival, physical activity, length of hospital stay and other complications (16)(17)(18)(19)(20)(21)(22). However, we found that current studies were limited to speci c primary tumors or site-speci c metastatic cancers (23)(24)(25). While sarcopenia as a systemic disease, we hypothesize that it is closely associated with the prognosis of multiple metastatic cancers.…”

Section: Introductionmentioning

confidence: 79%

Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis

Zhou

Shen

Fang

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Metastasis of cancer causes more than 90% of cancer deaths and is severely damaging to human health. In recent years, several studies have linked sarcopenia to shorter survival in patients with metastatic cancer. Several predictive models exist to predict mortality in patients with metastatic cancer, but have reported limited accuracy. Methods We systematically searched PubMed, EMBASE, and the Cochrane Library for articles published on or before October 14, 2022. Pooled Hazard Ratio (HR) estimates with 95% confidence intervals (CIs) were calculated using a random effects model. The primary outcome was an increased risk of death or tumor progression in patients with metastatic cancer. In addition, we performed subgroup analyses and leave-one-out sensitivity analyses to explore the main sources of heterogeneity and the stability of the results. Results Sixteen retrospective cohort studies with 1,675 patients were included in the 888 papers screened. The results showed that sarcopenia was associated with lower progression-free survival (HR = 1.56, 95% CI = 1.19–2.03, I2 = 76.3%, P < 0.001). This result was further confirmed by trim-and-fill procedures and leave-one-out sensitivity analysis. Conclusions This study suggests that sarcopenia may be a risk factor for reduced progression-free survival in patients with metastatic cancer. Further studies are still needed to explain the reason for this high heterogeneity in outcome. Trial Registration: CRD42022325910

show abstract

Section: Introductionmentioning

confidence: 79%

Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis

Zhou

Shen

Fang

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Previous meta-analyses have found an association of LSMM with OS after local therapy for CRC liver metastases [20]. For instance, Levolger et al found poorer OS in patients with LSMM undergoing surgery for gastrointestinal hepatopancreatobiliary malignancies [37].…”

Section: Discussionmentioning

confidence: 99%

“…Prognostic indicators for patient outcome after liver surgery are wanted. It is known that age, performance status, comorbidities, and lymph node status, among others, influence post-operative complications and outcome [20,21]. However, discriminatory accuracy of prognostic scores has been limited [22].…”

Section: Introductionmentioning

confidence: 99%

Low skeletal muscle mass and post-operative complications after surgery for liver malignancies: a meta-analysis

Thormann

Omari

Pech

et al. 2022

Langenbecks Arch Surg

View full text Add to dashboard Cite

Purpose To assess the influence of low skeletal muscle mass (LSMM) on post-operative complications in patients with hepatic malignancies grade (Clavien Dindo ≥ 3) undergoing resection. Methods MEDLINE, Cochrane, and SCOPUS databases were screened for associations between sarcopenia and major post-operative complications (≥ grade 3 according to Clavien-Dindo classification) after resection of different malignant liver tumors. RevMan 5.3 software was used to perform the meta-analysis. The methodological quality of the included studies was assessed according to the QUIPS instrument. Results The analysis included 17 studies comprising 3157 patients. Subgroup analyses were performed for cholangiocarcinoma (CCC), colorectal cancer (CRC) liver metastases, and hepatocellular carcinoma (HCC). LSMM as identified on CT was present in 1260 patients (39.9%). Analysis of the overall sample showed that LSMM was associated with higher post-operative complications grade Clavien Dindo ≥ 3 (OR 1.56, 95% CI 1.25–1.95, p < 0.001). In the subgroup analysis, LSMM was associated with post-operative complications in CRC metastases (OR 1.60, 95% CI 1.11–2.32, p = 0.01). In HCC and CCC sub-analyses, LSMM was not associated with post-operative complications in simple regression analysis. Conclusion LSMM is associated with major post-operative complications in patients undergoing surgery for hepatic metastases and it does not influence major post-operative complications in patients with HCC and CCC.

show abstract

“…Previous studies indicate that colorectal cancer patients with sarcopenia have an inferior OS ( 31 ). Moreover, some of the studies indicated that sarcopenia was an independent predictor of long-term survival in colorectal liver metastases (CRLM) receiving liver resection ( 32 – 34 ). Additionally, van Dijk et al .…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Preoperative Sarcopenia in Patients With Gastric Cancer Liver Metastases Receiving Hepatectomy

Xiong

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

BackgroundThe present work focused on assessing the role of computed tomography (CT)-determined sarcopenia in the prognosis of patients with gastric cancer liver metastases (GCLM) receiving hepatectomy.MethodsWe analyzed data collected from GCLM cases that underwent hepatectomy between March 2011 and July 2017. The third lumbar vertebra (L3) level skeletal muscle index (SMI) was analyzed by abdominal CT to determine the sarcopenia before surgery. The thresholds for CT-based sarcopenia of sex-specific L3 SMI were ≤ 34.9 cm2/m2 and ≤ 40.8 cm2/m2 for female and male, separately We determined overall survival (OS) and recurrence-free survival (RFS)by univariate and multivariate analyses.ResultsThe cohort enrolled altogether 114 patients with GCLM receiving hepatectomy (average age: 62.6 years, male: 79.8%), and 58 (50.8%) patients had sarcopenia. The mean SMI was 34.2 in patients with sarcopenia compared to 42.7 in patients without sarcopenia (p < 0.001). The 1-, 3-, and 5-year OS rates in patients with GCLM after hepatectomy were 78.1, 43.7, and 34.3%, respectively. The 1-, 3-, and 5-year RFS rates in patients were 49.8, 33.6, and 29.3%, respectively. Sarcopenia was related to an advanced age (≥65.0 years) (p = 0.009), reduced BMI (<18.5 kg/m2) (p < 0.001) and number of liver metastases (>1) (p = 0.025). Sarcopenia had a significant associated with the patterns of recurrence (p < 0.001). In addition, patients with sarcopenia had a significant difference in number of liver metastases in comparison with those without sarcopenia (p = 0.025). We discovered from multivariate analysis that sarcopenia independently predicted RFS [hazard ratio (HR) = 1.76; 95% confidence interval (CI)= 1.18–2.35, p = 0.007]. Nevertheless, sarcopenia was not the prognostic factors that independently predicted OS (HR = 1.62; 95% CI = 0.57–2.73; p = 0.330).ConclusionsIn conclusion, we showed that CT-determined sarcopenia was the facile and effective prognostic factor for RFS inpatients with GCLM after hepatectomy. Patients with sarcopenia are associated with an increased tumor recurrence risk, and thereby customized treatment should be applied.

show abstract

Sarcopenia and long-term survival outcomes after local therapy for colorectal liver metastasis: a meta-analysis

Cited by 14 publications

References 46 publications

Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis

Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis

Low skeletal muscle mass and post-operative complications after surgery for liver malignancies: a meta-analysis

Prognostic Significance of Preoperative Sarcopenia in Patients With Gastric Cancer Liver Metastases Receiving Hepatectomy

Contact Info

Product

Resources

About